SEC Form 4 · accession 0001209191-17-052684
MERRIMACK PHARMACEUTICALS INC · MACK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ulrik B. Nielsen
Director
Period of report
Sep 11, 2017
Accepted (ET)
Sep 13, 2017 · 5:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274792
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 11, 2017 | M | 14,756 | $13.20 | A | 37,437 | D | |
| Common StockF1 | Sep 11, 2017 | S | 14,756 | $14.46 | D | 22,681 | D | |
| Common Stock | Sep 13, 2017 | M | 6,800 | $13.20 | A | 29,481 | D | |
| Common StockF2,F3 | Sep 13, 2017 | S | 6,800 | $14.27 | D | 22,681 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4,F5 | $13.20 | Sep 11, 2017 | M | 14,756 | D | — | Oct 4, 2017 | Common Stock | 14,756 | 14,033 | D |
| Stock Option (right to buy)F4,F5 | $13.20 | Sep 13, 2017 | M | 6,800 | D | — | Oct 4, 2017 | Common Stock | 6,800 | 7,233 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.43 to $14.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.15 to $14.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F3The one-for-ten reverse stock split of the Issuer's common stock that became effective for trading purposes on September 6, 2017 resulted in the reporting person's ownership of 204,130 fewer shares of common stock.
- F4This option was previously reported as covering 146,622 shares of common stock at an exercise price of $2.59 per share, but was adjusted to reflect both the special cash dividend that was payable on May 26, 2017 and the reverse stock split that became effective for trading purposes on September 6, 2017.
- F5This option is fully vested.